11:41 AM EST - InNexus Biotechnology Inc. : announced that it has developed IXS312(VEGF), an antibody fragment with activity against the growth factor VEGF for planned use in ocular treatments. Age-related macular degeneration (AMD) affects more than 30 million people worldwide and is the leading cause of blindness in people over 60 years of age in the U.S. InNexus Biotechnology Inc.
shares V.IXS are trading down $0.005 at $0.03.
